Knoxville, Tennessee-based Provectus Biopharmaceuticals Inc.'s shares finished Friday's session 21.53% higher at $0.02. A total volume of 11.51 million shares was traded, which was above their three months average volume of 3.87 million shares. The stock is trading below its 50-day moving average by 51.27%. Moreover, shares of Provectus Biopharma, which engages in developing ethical pharmaceuticals for oncology and dermatology indications, have a Relative Strength Index (RSI) of 39.85.
On December 22nd, 2016, Provectus Biopharmaceuticals announced acceptance of two abstracts for poster presentations at international oncology conferences in February 2017. Both abstracts describe data from the Company's phase 1 study of PV-10 in tumors of the liver. The first abstract, titled "Percutaneous Rose Bengal as an Ablative Immunotherapy for Hepatic Metastases," to be presented at Clinical Interventional Oncology (CIO) on February 4th-5th, 2017, in Hollywood, Florida, focuses on outcome in patients with colorectal cancer that has metastasized to the liver. The second abstract, titled "Intralesional Rose Bengal as an Ablative Immunotherapy for Hepatic Tumors," to be presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) on February 15th-19th, 2017, in Shanghai, China, focuses on outcome in patients with hepatocellular carcinoma. PVCT complete research report is just a click away and free at:
Shares in Basel, Switzerland headquartered Novartis AG ended the day 0.11% higher at $71.85 with a total trading volume of 1.47 million shares. The stock has advanced 4.42% in the last month. The Company's shares are trading 0.48% above their 50-day moving average. Moreover, shares of Novartis, which researches, develops, manufactures, and markets a range of healthcare products worldwide, have an RSI of 58.47.
On December 20th, 2016, Novartis announced that it has entered into a definitive agreement for the acquisition of Encore Vision, Inc., a privately-held company in Fort Worth, Texas, USA, focused on the development of a novel treatment in presbyopia. This acquisition would add a first-in-class disease modifying topical treatment for presbyopia to the Novartis ophthalmology pipeline, providing a potentially disruptive innovation to patients in a new therapeutic area of high unmet need and high prevalence. The transaction is subject to customary closing conditions, including regulatory approval. The financial details of this transaction were not disclosed. The complimentary report on NVS can be downloaded at:
Boca Raton, Florida headquartered TherapeuticsMD Inc.'s stock rose 4.73%, closing the session at $5.98 with a total trading volume of 1.79 million shares. Shares of the Company, which operates as a women's health care product company, are trading 2.64% below their 50-day moving average. The stock has an RSI of 48.13.
On December 5th, 2016, TherapeuticsMD announced positive top-line results from its pivotal phase 3 Replenish Trial of TX-001HR, an investigational bio-identical hormone therapy combination of 17ß-estradiol and progesterone in a single, oral softgel, for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause in post-menopausal women with an intact uterus. The Replenish Trial evaluated four doses of TX-001HR and placebo in 1,835 post-menopausal women between 40 and 65 years old. Sign up for your complimentary research report on TXMD at:
On Friday, shares in New York-based Tonix Pharmaceuticals Holding Corp. finished the session 3.23% lower at $0.48. A total volume of 914,673 shares was traded. The stock has surged 26.22% in the last month. The Company's shares are trading above their 50-day moving average by 2.25%. Furthermore, shares of Tonix Pharma, which develops medicines for common disorders of the central nervous system, have an RSI of 55.25.
On December 19th, 2016, Tonix Pharmaceuticals announced that the US FDA has granted Breakthrough Therapy designation to TNX-102 SL* for the treatment of posttraumatic stress disorder (PTSD). The benefits of Breakthrough Therapy designation include the eligibility for priority review of the New Drug Application (NDA) within 6 months instead of 10 months and rolling submission of portions of the NDA. Tonix held a successful End-of-Phase 2/Pre-Phase 3 meeting with the FDA in Q3 2016, based on positive data from its 12-week randomized, double-blind, placebo-controlled Phase 2 AtEase study. Tonix plans to begin enrolling patients into its first Phase 3 study, the HONOR study, in Q1 2017 after receiving FDA agreement on the study design and interim analysis plan. Get free access to your research report on TNXP at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA